White paper urges FDA to act against companies producing counterfeit GLP-1s
New Standards of Care offer ‘tailor-made recommendations’ for treating obesity
Tirzepatide bests semaglutide for weight loss in adults with obesity
NovoCare Pharmacy may improve access to Wegovy, but concerns about affordability remain
Senate bill aims to curtail social media influencer, telehealth drug misinformation
Read at Healio
Tirzepatide led to greater real-world weight loss than semaglutide for adults with obesity
Read at Healio
“Tremendous progress” of anti-obesity medications in last decade
Watch at Healio
Importance of personalized, multifactorial treatment plans for patients with obesity
Watch at Healio
Lifestyle intervention critical for obesity prevention, treatment
Watch at Healio
Barriers to care persist amid increasing recognition of obesity as a chronic disease
Watch at Healio
Addressing disparities in obesity care
Watch at Healio
Expert discusses collaboration between obesity medicine physicians, PCPs
Watch at Healio
Patients with obesity are giving us another chance – let’s not squander it
Read at Healio
Most adults with obesity are not prescribed obesity medication
Though awareness about obesity is growing, many adults who would benefit from anti-obesity medications aren’t getting them. Dr. Katherine Saunders lays out some of the
Tirzepatide earns FDA approval for obesity treatment
The dual agonist medication has FDA approval for weight loss Enabling an average of 26% weight loss, Zepbound is a potential game changer for patients
Intermittent therapy may be a ‘practical strategy’ for maintaining weight loss
Though obesity is a chronic condition needing lifelong treatment, it may not require constant use of anti-obesity medications. So argued Dr. Lee Kaplan during an
New anti-obesity medications: With great power comes great responsibility
As the saying goes, “With great power comes great responsibility.” This is especially true with weight loss medications. To set patients up for success, Intellihealth
Adults with obesity using tirzepatide maintain ‘remarkable’ weight loss at 88 weeks
New findings from the SURMOUNT-4 trial showed that participants using tirzepatide lost more than a quarter of their body weight, results on par with bariatric
Has Disease Recognition Improved Access to Obesity Care?
Q&A with Dr. Saunders about 10-year Anniversary In a conversation with Healio, Dr. Katherine Saunders reflects on past ten years of obesity medicine and how
